EquitySector - HealthcareVery High Risk
Direct
NAV (02-Sep-25)
Returns (Since Inception)
Fund Size
₹112 Cr
Expense Ratio
0.66%
ISIN
INF663L01Z45
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
06 Dec 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
-0.80%
— (Cat Avg.)
Equity | ₹109.83 Cr | 97.78% |
Others | ₹2.5 Cr | 2.22% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹14.12 Cr | 12.57% |
Divi's Laboratories Ltd | Equity | ₹9.34 Cr | 8.31% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹8.67 Cr | 7.72% |
Dr Reddy's Laboratories Ltd | Equity | ₹6.97 Cr | 6.21% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹6.16 Cr | 5.48% |
Mankind Pharma Ltd | Equity | ₹5.76 Cr | 5.13% |
Torrent Pharmaceuticals Ltd | Equity | ₹5.01 Cr | 4.46% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹4.4 Cr | 3.92% |
Abbott India Ltd | Equity | ₹4.09 Cr | 3.64% |
Ajanta Pharma Ltd | Equity | ₹3.92 Cr | 3.49% |
Global Health Ltd | Equity | ₹3.47 Cr | 3.09% |
PB Fintech Ltd | Equity | ₹3.2 Cr | 2.85% |
Cipla Ltd | Equity | ₹3.06 Cr | 2.73% |
Dr. Lal PathLabs Ltd | Equity | ₹2.98 Cr | 2.65% |
Navin Fluorine International Ltd | Equity | ₹2.89 Cr | 2.58% |
ICICI Lombard General Insurance Co Ltd | Equity | ₹2.7 Cr | 2.40% |
Jupiter Life Line Hospitals Ltd | Equity | ₹2.64 Cr | 2.35% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹2.39 Cr | 2.13% |
Ipca Laboratories Ltd | Equity | ₹2.37 Cr | 2.11% |
Sagility India Ltd | Equity | ₹2.33 Cr | 2.07% |
Rainbow Childrens Medicare Ltd | Equity | ₹2.29 Cr | 2.04% |
Neuland Laboratories Ltd | Equity | ₹2.25 Cr | 2.00% |
Clearing Corporation Of India Ltd. | Cash - Repurchase Agreement | ₹2.17 Cr | 1.93% |
Syngene International Ltd | Equity | ₹1.86 Cr | 1.66% |
Sanofi India Ltd | Equity | ₹1.69 Cr | 1.50% |
Sai Life Sciences Ltd | Equity | ₹1.53 Cr | 1.37% |
Anthem Biosciences Ltd | Equity | ₹1.21 Cr | 1.07% |
Zydus Lifesciences Ltd | Equity | ₹1.14 Cr | 1.02% |
Orchid Pharma Ltd | Equity | ₹0.87 Cr | 0.78% |
Dr Agarwal'S Eye Hospital Ltd | Equity | ₹0.52 Cr | 0.46% |
Net Receivables / (Payables) | Cash | ₹0.33 Cr | 0.30% |
Large Cap Stocks
48.13%
Mid Cap Stocks
17.58%
Small Cap Stocks
30.99%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹101.04 Cr | 89.94% |
Financial Services | ₹5.9 Cr | 5.26% |
Basic Materials | ₹2.89 Cr | 2.58% |
Standard Deviation
This fund
--
Cat. avg.
15.89%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.99
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.79
Higher the better
Since January 2025
Since January 2025
Since January 2025
Since January 2025
ISIN INF663L01Z45 | Expense Ratio 0.66% | Exit Load No Charges | Fund Size ₹112 Cr | Age 8 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Total AUM
₹25,553 Cr
Address
Nirlon House, 2nd Floor, Mumbai, 400 030
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Direct
NAV (02-Sep-25)
Returns (Since Inception)
Fund Size
₹112 Cr
Expense Ratio
0.66%
ISIN
INF663L01Z45
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
06 Dec 2024
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
-0.80%
— (Cat Avg.)
Equity | ₹109.83 Cr | 97.78% |
Others | ₹2.5 Cr | 2.22% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹14.12 Cr | 12.57% |
Divi's Laboratories Ltd | Equity | ₹9.34 Cr | 8.31% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹8.67 Cr | 7.72% |
Dr Reddy's Laboratories Ltd | Equity | ₹6.97 Cr | 6.21% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹6.16 Cr | 5.48% |
Mankind Pharma Ltd | Equity | ₹5.76 Cr | 5.13% |
Torrent Pharmaceuticals Ltd | Equity | ₹5.01 Cr | 4.46% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹4.4 Cr | 3.92% |
Abbott India Ltd | Equity | ₹4.09 Cr | 3.64% |
Ajanta Pharma Ltd | Equity | ₹3.92 Cr | 3.49% |
Global Health Ltd | Equity | ₹3.47 Cr | 3.09% |
PB Fintech Ltd | Equity | ₹3.2 Cr | 2.85% |
Cipla Ltd | Equity | ₹3.06 Cr | 2.73% |
Dr. Lal PathLabs Ltd | Equity | ₹2.98 Cr | 2.65% |
Navin Fluorine International Ltd | Equity | ₹2.89 Cr | 2.58% |
ICICI Lombard General Insurance Co Ltd | Equity | ₹2.7 Cr | 2.40% |
Jupiter Life Line Hospitals Ltd | Equity | ₹2.64 Cr | 2.35% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹2.39 Cr | 2.13% |
Ipca Laboratories Ltd | Equity | ₹2.37 Cr | 2.11% |
Sagility India Ltd | Equity | ₹2.33 Cr | 2.07% |
Rainbow Childrens Medicare Ltd | Equity | ₹2.29 Cr | 2.04% |
Neuland Laboratories Ltd | Equity | ₹2.25 Cr | 2.00% |
Clearing Corporation Of India Ltd. | Cash - Repurchase Agreement | ₹2.17 Cr | 1.93% |
Syngene International Ltd | Equity | ₹1.86 Cr | 1.66% |
Sanofi India Ltd | Equity | ₹1.69 Cr | 1.50% |
Sai Life Sciences Ltd | Equity | ₹1.53 Cr | 1.37% |
Anthem Biosciences Ltd | Equity | ₹1.21 Cr | 1.07% |
Zydus Lifesciences Ltd | Equity | ₹1.14 Cr | 1.02% |
Orchid Pharma Ltd | Equity | ₹0.87 Cr | 0.78% |
Dr Agarwal'S Eye Hospital Ltd | Equity | ₹0.52 Cr | 0.46% |
Net Receivables / (Payables) | Cash | ₹0.33 Cr | 0.30% |
Large Cap Stocks
48.13%
Mid Cap Stocks
17.58%
Small Cap Stocks
30.99%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹101.04 Cr | 89.94% |
Financial Services | ₹5.9 Cr | 5.26% |
Basic Materials | ₹2.89 Cr | 2.58% |
Standard Deviation
This fund
--
Cat. avg.
15.89%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.99
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.79
Higher the better
Since January 2025
Since January 2025
Since January 2025
Since January 2025
ISIN INF663L01Z45 | Expense Ratio 0.66% | Exit Load No Charges | Fund Size ₹112 Cr | Age 8 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Total AUM
₹25,553 Cr
Address
Nirlon House, 2nd Floor, Mumbai, 400 030
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments